Evidence for predominance of CCR5-using HIV-1 strains during highly active antiretroviral therapy

Current HIV Research

Volumn 5, Issue 2, 2007, Pages 221-234

  Wang, Yuan Min ^a,e   Wang, Bin ^a   Dyer, Wayne B ^b   Lachireddy, Kishen ^b,c   Peng, Ng Kee ^d   Saksena, Nitin K ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

^c Health Risk Policy Advice Section ^*  (Australia)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

CCR5; Co receptor expression; HAART; HIV; STI

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DIDANOSINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GAG PROTEIN;

CLINICAL ARTICLE; DATA ANALYSIS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; VIROGENESIS; VIRUS REPLICATION; VIRUS STRAIN; ARTICLE; DOWN REGULATION; DRUG ADMINISTRATION; DRUG EFFECT; METABOLISM; MONONUCLEAR CELL; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; RECEPTORS, CCR5; RECEPTORS, CXCR4; T-LYMPHOCYTES;

EID: 33947584907     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207780077048     Document Type: Review

References (35)

1. Andersson J, Fehniger TE, Patterson BK, Pottage J, Agnoli M, Jones P, Behbahani H, Landay A. (1998). Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS. 12: F123-129.
2. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, Leibowitch J. (1997). Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 277: 112-116.
3. Bjorndal A, Deng H, Jansson M., Fiore JR, Colognesi C, Karlsson A, Albert J, Scarlatti G, Littman DR, Fenyo EM. (1997). Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype. Journal of Virology. 71: 7478-7487.
4. Bleul CC, Wu L, Hoxie JA, Springer TA, Mackay CR. (1997). The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proceeding of the National Academy of Sciences of the United States of America. 94: 1925-1930.
5. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. (1997). Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. Journal of Experimental Medicine. 185: 621-628.
6. Dean M. (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science. 273: 1856-1862.
7. Doranz BJ, Rucker J, Yi Y, Smyth RJ, Samson M, Peiper SC, Parmentier M, Collman RG, Doms RW. (1996). A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell. 85: 1149-1158.
8. Felsenstein J. (1993). PHYLIP (Phylogeny Inference Package), version 3.56c. Seattle: University of Washington, USA.
9. Giovanetti A, Ensoli F, Mazzetta M, De Cristofaro M, Pierdominici M, Muratori S. (1999). CCR5 and CXCR4 chemokine receptor expression and beta chemokine production during early T cell repolulation induced by HAART. Clinical and Experimental Immunology. 118: 87-94.
10. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, He T, Kang S, Ceradini D, Jin Z, Yazdanbakhsh K, Kunstman K, Erickson D, Dragon E, Landau NR, Phair J, Ho DD, Koup RA. (1996). The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nature Medicine. 2: 1240-1243.
11. Jensen MA, Li FS, van 't Wout AB, Nickle DC, Shriner D, He HX, McLaughlin S, Shankarappa R, Margolick JB, Mullins JI. (2003). Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. Journal of Virology. 77: 13376-13388.
12. Kozak SL, Platt EJ, Madani N, Ferro FEJ, Peden K, Kabat D. (1997), CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1. Journal of Virology. 71: 873-882.
13. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. (1998). Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet. 351: 1682-1686.
14. Lin YL, Mettling C, Portales P, Reynes J, Clot J, Corbeau P. (2002). Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection. Proceeding of the National Academy of Sciences of United States of America. 99: 15590-15595.
15. Manetti R, Cosmi L, Galli G, Annunziato F, Mazzetti M, Romagnani S, Maggi E. (2000). Enhanced expression of the CXCR4 co-receptor in HIV-1-infected individuals correlates with the emergence of syncytia-inducing strains. Cytokines Cell Molecular Therapy. 6: 19-24.
16. Masciotra S, Owen SM, Rudolph D, Yang C, Wang B, Saksena N, Spira T, Dhawan S, Lal RB. (2002). Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS. 16: 1887-1898.
17. Michael NL, Louie LG, Rohrbaugh AL, Schultz KA, Dayhoff DE, Wang CE, Sheppard HW. (1997). The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression. Nature Medicine. 3: 1160-1162.
18. Moore JP. (1997). Coreceptors: implications for HIV pathogenesis and therapy. Science. 276: 51-52.
19. Nokta MA, Li XD, Nichols J, Mallen M, Pou A, Asmuth D, Pollard RB. (2001). Chemokine/CD4 receptor density ratios correlate with HIV replication in lymph node and peripheral blood of HIV-infected individuals. AIDS. 15: 161-169.
20. Ostrowski MA, Justement SJ, Cantanzaro A, Hallahan CA, Ehler LA, Mizell SB, Kumar PN, Mican JA, Chun TW, Fauci A. (1998). Expression of Chemokine receptors and CCR5 in HIV-1 infected and uninfected individuals. Journal of Immunology. 161: 3195-3201.
21. Pakker NG, Roos MT, van Leeuwen R, de Jong MD, Koot M, Reiss P, Lange JM, Miedema F, Danner SA, Schellekens PT. (1997). Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 16: 318-326.
22. Penn ML, Grivel JC, Schramm B, Goldsmith MA, Margolis L. (1999). CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue. Proceeding of the National Academy of Sciences of the United States of America. 96: 663-668.
23. Philpott S, Weiser B, Anastos K, Kitchen CM, Robison E, Meyer WA 3rd, Sacks HS, Mathur-Wagh U, Brunner C, Burger H. (2001). Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. The Journal of Clinical Investigation. 107: 431-438.
24. Philpott SM. (2003). HIV-1 coreceptor usage, transmission, and disease progression. Currunt HIV Research, 1: 217-227.
25. Pierdominici M, Giovanetti A, Ensoli F, Mazzetta F, Marziali M, De Cristofaro MR, Santini-Muratori D, Leti W, Aiuti F. (2002). Changes in CCR5 and CXCR4 expresssion and beta chemokine production in HIV-infected patients treated with HAART. AIDS. 29: 122-131.
26. Reynes J, Portales P, Segondy M, Baillat V, Andre P, Avinens O, Picot MC, Clot J, Eliaou JF, Corbeau P. (2001). CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression. AIDS. 15: 1627-1634.
27. Saksena NK, Potter SJ. (2003). Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Reviews. 5: 3-18.
28. Scarlatti G, Tresoldi E, Bjorndal A, Fredriksson R, Colognesi C, Deng HK, Malnati MS, Plebani A, Siccardi AG, Littman DR, Fenyo EM, Lusso P. (1997). In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nature Medicine. 3: 1259-1265.
29. Schuitemaker H, Kootstra NA, Groenink M, De Goede RE, Miedema F, Tersmette M. (1992). Differential tropism of clinical HIV-1 isolates for primary monocytes and promonocytic cell lines. AIDS Research and Human Retroviruses. 8: 1679-1682.
30. Skrabal K, Trouplin V, Labrosse B, Obry V, Damond F, Hance AJ, Clavel F, Mammano F. (2003). Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS. 17: 809-814.
31. Thompson JD, Higgins DG, Gibson TJ. (1994). CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Research 22: 4673-4680.
32. van Rij RP, Blaak H, Visser JA, Brouwer M, Rientsma R, Broersen S, de Roda Husman AM, Schuitemaker H. (2000). Differential coreceptor expression allows for independent evolution of nonsyncytium-inducing and syncytium-inducing HIV-1. Journal of Clinical Investigation. 106: 1039-1052.
33. Wang YM, Dyer WB, Workman C, Wang B, Sullivan JS, Saksena NK. (2000). Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to the HAART. AIDS. 14: 2265-2272.
34. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Brown AJ, Simmonds P. (1993). Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. Journal of Virology. 67: 3345-3356.
35. Zhu T, Mo H, Wang N, Nam DS, Cao Y, Koup RA, Ho DD. (1993). Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 261: 1179-1181.